BMRN

55.27

0.36% -0.20

Dopo l'orario di chiusura: 55.27

Biomarin Pharmaceutical Inc (BMRN)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

$55.47

Aprire:

$56

Volume 24 ore:

1.15M

Relative Volume:

0.55

Capitalizzazione di mercato:

$10.63B

Reddito:

$3.24B

Utile/perdita netta:

$348.90M

Rapporto P/E:

31.02

EPS:

1.7817

Flusso di cassa netto:

$717.02M

1 W Prestazione:

-3.37%

1M Prestazione:

-5.54%

6M Prestazione:

+4.11%

1 anno Prestazione:

-7.91%

Intervallo 1D:

$54.99

$56.05

Intervallo di 1 settimana:

$53.88

$57.09

Portata 52W:

$50.76

$66.28

Biomarin Pharmaceutical Inc Stock (BMRN) Company Profile

Nome

Biomarin Pharmaceutical Inc

Settore

Healthcare (1112)

Industria

Biotechnology (621)

Telefono

(415) 506-6700

Indirizzo

105 DIGITAL DRIVE, NOVATO, CA

Dipendente

3,221

Cinguettio

Prossima data di guadagno

2026-02-23

Ultimi documenti SEC

BMRN's Discussions on Twitter

Compare BMRN vs VRTX, REGN, ARGX, ALNY, ONC

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
BMRN Biomarin Pharmaceutical Inc	55.27	10.67B	3.24B	348.90M	717.02M	1.7817
VRTX Vertex Pharmaceuticals Inc	441.70	113.01B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	753.93	79.87B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	840.87	51.51B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	333.39	45.29B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	319.94	34.41B	5.36B	287.73M	924.18M	2.5229

Biomarin Pharmaceutical Inc Stock (BMRN) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-01-28	Ripresa	Barclays	Overweight
2026-01-20	Aggiornamento	Canaccord Genuity	Hold → Buy
2025-12-03	Downgrade	Leerink Partners	Outperform → Market Perform
2025-11-06	Downgrade	Stifel	Buy → Hold
2025-09-08	Iniziato	H.C. Wainwright	Neutral
2025-09-03	Iniziato	Raymond James	Outperform
2025-07-03	Ripresa	Morgan Stanley	Overweight
2025-02-24	Aggiornamento	Oppenheimer	Perform → Outperform
2024-11-15	Iniziato	Wolfe Research	Outperform
2024-10-30	Downgrade	William Blair	Outperform → Mkt Perform
2024-10-10	Ripresa	Raymond James	Outperform
2024-08-20	Aggiornamento	Bernstein	Mkt Perform → Outperform
2024-05-17	Downgrade	Robert W. Baird	Outperform → Neutral
2024-05-14	Iniziato	Evercore ISI	Outperform
2023-11-15	Iniziato	Wells Fargo	Overweight
2023-10-23	Aggiornamento	Bernstein	Underperform → Mkt Perform
2023-09-28	Iniziato	Raymond James	Mkt Perform
2023-09-18	Iniziato	UBS	Buy
2023-07-27	Iniziato	Scotiabank	Sector Perform
2023-07-05	Aggiornamento	BMO Capital Markets	Market Perform → Outperform
2023-06-14	Ripresa	Credit Suisse	Outperform
2023-03-21	Iniziato	Bernstein	Underperform
2023-02-22	Downgrade	Oppenheimer	Outperform → Perform
2023-02-21	Iniziato	Citigroup	Neutral
2023-01-30	Iniziato	BMO Capital Markets	Market Perform
2023-01-18	Iniziato	Canaccord Genuity	Hold
2022-10-31	Aggiornamento	Oppenheimer	Perform → Outperform
2022-07-13	Iniziato	Cantor Fitzgerald	Overweight
2022-06-13	Ripresa	Wedbush	Neutral
2022-04-25	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2021-11-22	Aggiornamento	William Blair	Mkt Perform → Outperform
2021-10-07	Ripresa	Jefferies	Buy
2021-09-09	Aggiornamento	Stifel	Hold → Buy
2021-06-04	Ripresa	Robert W. Baird	Outperform
2021-04-26	Ripresa	Credit Suisse	Outperform
2021-03-04	Ripresa	Guggenheim	Buy
2021-03-01	Aggiornamento	Evercore ISI	In-line → Outperform
2020-08-20	Downgrade	Citigroup	Buy → Neutral
2020-08-20	Downgrade	William Blair	Outperform → Mkt Perform
2020-08-19	Downgrade	Evercore ISI	Outperform → In-line
2020-08-19	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
2020-08-19	Downgrade	Stifel	Buy → Hold
2020-07-08	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2020-07-06	Reiterato	Citigroup	Buy
2020-01-28	Iniziato	BMO Capital Markets	Market Perform
2020-01-27	Iniziato	BMO Capital Markets	Market Perform
2020-01-24	Aggiornamento	RBC Capital Mkts	Sector Perform → Outperform
2019-11-27	Aggiornamento	Barclays	Equal Weight → Overweight
2019-11-12	Iniziato	SunTrust	Buy
2019-10-17	Ripresa	BofA/Merrill	Buy
2019-05-23	Ripresa	Citigroup	Buy
2019-04-09	Ripresa	Raymond James	Outperform
2019-01-02	Downgrade	Raymond James	Outperform → Mkt Perform
2018-12-14	Iniziato	Wolfe Research	Outperform
2018-10-01	Iniziato	Cantor Fitzgerald	Overweight
2018-08-07	Reiterato	Stifel	Buy
2018-08-03	Reiterato	Stifel	Buy

Mostra tutto

Biomarin Pharmaceutical Inc Borsa (BMRN) Ultime notizie

04:05 AM

Here Is Why BioMarin (BMRN) Is Projected to Rally - MSN

04:05 AM

12:54 PM

BioMarin Pharmaceutical's Rare Disease Portfolio Supplemented By Amicus Acquisition Makes A Buy - Seeking Alpha

12:54 PM

Apr 14, 2026

BioMarin Pharmaceutical stock (US09061G1013): Is rare disease leadership strong enough to unlock new - AD HOC NEWS

Apr 14, 2026

Apr 13, 2026

Paragon Capital Invests $1.19M in BioMarin Pharmaceutical - National Today

Apr 13, 2026

Apr 12, 2026

Is BioMarin Pharmaceutical (BMRN) Now Attractive After Prolonged Share Price Weakness? - Yahoo Finance

Apr 12, 2026

Apr 10, 2026

Is It Time To Reassess BioMarin Pharmaceutical (BMRN) After A 42.7% Three-Year Share Price Fall - Sahm

Apr 10, 2026

Apr 09, 2026

RBC Capital Sticks to Their Hold Rating for BioMarin Pharmaceutical (BMRN) - The Globe and Mail

Apr 09, 2026

Game Over- No Self-Help Clock Reset for Mandatory Stay Request - The National Law Review

Apr 09, 2026

Apr 08, 2026

Trading the Move, Not the Narrative: (BMRN) Edition - Stock Traders Daily

Apr 08, 2026

Apr 07, 2026

BioMarin Pharmaceutical Secures European Regulatory Approval for Amicus Therapeutics Acquisition - marketscreener.com

Apr 07, 2026

Apr 05, 2026

BioMarin Pharmaceutical (BMRN) receives FDA approval for expanded use of PALYNZIQ in adolescents - MSN

Apr 05, 2026

Perpetual Ltd Grows Stake in BioMarin Pharmaceutical Inc. $BMRN - marketbeat.com

Apr 05, 2026